报价延迟最少15分钟:2025/11/22 20:18 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
547.96 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-12.91/-1.48
|
|
企业价值
12.43B
|
| 资产负债 |
|
每股账面净值
27.55
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
180.13M
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH. |
